Sweden’s Sobi and US biopharma Apellis Pharmaceuticals have presented new data from the open-label period of the Phase III ...

The VALIANT Phase 3 trial shows that pegcetacoplan significantly reduces proteinuria and stabilises kidney function in ...

Membranoproliferative glomerulonephritis (MPGN), also termed mesangiocapillary glomerulonephritis, is diagnosed on the basis of a glomerular-injury pattern that is common to a heterogeneous group ...

Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating Aspaveli® (pegcetacoplan) for C3 glomerulopathy (C3G ...

Robust proteinuria reduction and stable kidney function were maintained across a broad population of patients No new safety signals were observedNew data presented at late-breaking session at the ...

Glomerulonephritis is a type of kidney disease linked to inflammation of the tiny blood vessels in the kidneys known as glomeruli. It can result from streptococcal infections, certain diseases ...

Even if there are problems with the function, the kidneys do not have any special symptoms, making it difficult to recognize ...

Glomerulonephritis refers to several conditions that affect the structures within the kidneys that filter blood. Nephrotic syndrome refers to several symptoms that indicate the kidneys are not ...

Membranous glomerulonephritis (MGN) is a type of kidney disease. Symptoms include facial swelling, weight gain, and an excessive need to urinate. While there’s no cure for MGN, treatment can ...

Glomerulonephritis (GN) is characterised by inflammation of the glomeruli, which is the kidney's intricate network of filters, responsible for purifying blood by removing waste products and excess ...

Glomerulonephritis refers to acute and chronic kidney diseases caused by injury to the glomerulus, a part of the kidney responsible for filtering blood. If the kidney is injured, it is unable to ...

Sobi® (STO: SOBI) and Apellis Pharmaceuticals, Inc. today presented new data from the open-label period of the Phase 3 VALIANT study, investigating Aspaveli® ...